Christopher Bruno

Ceftolozane–tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial

Marin H. Kollef, Martin Nováček, Ülo Kivistik et al. · The Lancet Infectious Diseases · 2019 · 329 citations

Antibiotics, Nosocomial Pneumonia, Non-inferiority Trial +2

Ceftolozane/tazobactam versus meropenem in patients with ventilated hospital-acquired bacterial pneumonia: subset analysis of the ASPECT-NP randomized, controlled phase 3 trial

Jean‐François Timsit, Jennifer A. Huntington, Richard G. Wunderink et al. · Critical Care · 2021 · 46 citations · Full text

Pharmacokinetics and safety of posaconazole intravenous solution and powder for oral suspension in children with neutropenia: an open-label, sequential dose-escalation trial

Andreas H. Groll, Hisham Abdel‐Azim, Thomas Lehrnbecher et al. · International Journal of Antimicrobial Agents · 2020 · 43 citations

Drug Safety, Therapeutic Drug Monitoring, Medicine +6

Safety, tolerability, and immunogenicity of an adult pneumococcal conjugate vaccine, V116 (STRIDE-3): a randomised, double-blind, active comparator controlled, international phase 3 trial

Heather Platt, Christopher Bruno, Erik Buntinx et al. · The Lancet Infectious Diseases · 2024 · 41 citations

Vaccination, Vaccine Safety, Vaccine Development +6

The influence of abacavir and other antiretroviral agents on virological response to HCV therapy among antiretroviral-treated HIV-infected patients

Valerianna Amorosa, Jihad Slim, Karam Mounzer et al. · Antiviral Therapy · 2010 · 27 citations · Full text